OR WAIT 15 SECS
Sartorius Stedim Biotech has unveiled a new single-use vessel for its ambr 250 modular benchtop automated mini bioreactor system that has been specifically designed for therapeutic cell lines.
Sartorius Stedim Biotech (SSB) has unveiled a new single-use vessel for its ambr 250 modular benchtop automated mini bioreactor system that has been specifically designed for therapeutic cell lines in a June 27, 2019 press release.
The vessel design features a large pitched blade impeller that has a working volume of 100–250 mL, which allows for gentle stirring and mixing to aid cell line growth. The company states in the press release that according to trials with regenerative medicine companies, the mini bioreactor demonstrated improved cell culture performance compared with spinner or T-flask models.
Additionally, the ambr 250 modular system includes a motor (100 rpm–4500 prm) that, the company reports, is ideal for lower stirrer speeds that are required by delicate therapeutic cell lines. Furthermore, the bioreactor system is available with optional BioPAT MODDE software for design-of-experiments, and to support quality-by-design for scale up, to store bioreactors, and scale out, to rocking bags suitable for cGMP production of autologous and allogenic cell and gene therapies.
“The ambr 250 systems are established as [a] biopharma industry standard small-scale model for biologics process optimization, and we have been approached by numerous scientists developing cell and gene therapies to extend our technology for these applications,” explained Barney Zoro, ambr product manager at SSB. “We have responded by designing a new vessel for the ambr 250 modular system to provide a single-use platform, with a clear scalable pathway to our bioreactors and bags for clinical production of regenerative medicines.”